- Home
- KINS vs TIL Comparison
KINS vs TIL Comparison
Compare KINS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KINS
- TIL
- Stock Information
- Founded
- KINS 1886
- TIL 2018
- Country
- KINS United States
- TIL United States
- Employees
- KINS N/A
- TIL N/A
- Industry
- KINS Property-Casualty Insurers
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- KINS Finance
- TIL Health Care
- Exchange
- KINS Nasdaq
- TIL Nasdaq
- Market Cap
- KINS 228.3M
- TIL 230.1M
- IPO Year
- KINS N/A
- TIL 2021
- Fundamental
- Price
- KINS $14.75
- TIL $28.58
- Analyst Decision
- KINS Strong Buy
- TIL Buy
- Analyst Count
- KINS 1
- TIL 5
- Target Price
- KINS $6.50
- TIL $119.00
- AVG Volume (30 Days)
- KINS 264.4K
- TIL 504.0K
- Earning Date
- KINS 08-11-2025
- TIL 08-12-2025
- Dividend Yield
- KINS N/A
- TIL N/A
- EPS Growth
- KINS 5417.04
- TIL N/A
- EPS
- KINS 1.60
- TIL N/A
- Revenue
- KINS $169,875,701.00
- TIL N/A
- Revenue This Year
- KINS $40.63
- TIL N/A
- Revenue Next Year
- KINS $6.92
- TIL N/A
- P/E Ratio
- KINS $9.24
- TIL N/A
- Revenue Growth
- KINS 18.52
- TIL N/A
- 52 Week Low
- KINS $4.65
- TIL $9.62
- 52 Week High
- KINS $22.40
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- KINS 39.54
- TIL 51.88
- Support Level
- KINS $14.67
- TIL $34.76
- Resistance Level
- KINS $15.47
- TIL $42.79
- Average True Range (ATR)
- KINS 0.50
- TIL 5.38
- MACD
- KINS -0.04
- TIL -0.77
- Stochastic Oscillator
- KINS 6.32
- TIL 26.45
About KINS Kingstone Companies Inc.
Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.